Astellas Pharma Inc. · TSE:4503
Astellas Pharma — Merger or Acquisition (June 2018)
11 slides from Astellas Pharma's merger presentation, Jun 1, 2018
Slide 1: A New Alliance to Serve Patients in Japan
A New Alliance to Serve Patients in Japan Amgen Astellas BioPharma KK Yoshihiko Hatanaka Robert A. A Bradway President and CEO Chairman and CEO Astellas Pharma Inc. Amgen Astellas Pharma: Cautionary Statement Regarding Forward- L ki Looking Information I f ti This material includes forward-looking s
Slide 2: A New Alliance to Serve Patients in Japan
A New N Alliance Alli to t Serve S Patients P ti t ini JJapan Yoshihiko Hatanaka President and CEO Astellas Pharma Inc. Amgen and Astellas Strategic Alliance for the Japanese Market Long-term g collaboration Establish Joint Venture Company Amgen Astellas BioPharma KK
Slide 3: About Astellas; Strategic Alliance: Structure
About Astellas Focus on innovative pharmaceutical 1 3 Global expansion business Urology, Transplantation, Oncology, Own sales network in about 50 countries Immunology & Infectious Diseases, Neurosciences and DM Complications and Kid Kidney Diseases Di 4 Strong R&D capabilities 2 Solid foundation in
Slide 4: Strategic Alliance: Structure (continued) - Five Pipeline Medicines
Strategic g Alliance: Structure ((continued)) to be, on a product-by- Co-development p & co-commercialization of product basis basis, in place 5 pipeline medicines until 2032 at the latest Amgen Astellas BioPharma KK to become a wholly owned Amgen affiliate as soon as 2020 2020 2032 Five Pipeline p
Slide 5: Concept of Strategic Alliance
Concept p of Strategic g Alliance Amgen Astellas BioPharma KK Innovative • Leverage strengths • IIn-depth d th kknowledge l d off local medical needs medicines derived from biotechnology of both companies • A win-win • Long experience of Rapid delivery of relationship development, innovative regulat
Slide 6: Amgen Forward Looking Statement
Amgen g Forward Looking g Statement This presentation contains forward‐looking statements that are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All
Slide 7: Amgen: Unlocking the Potential of Biology for Patients
Our Mission to Serve Patients Amgen: g Unlocking g the Potential of Biology gy for Patients • Serious illnesses • Large unmet needs • Biology first
Slide 8: Amgen: Unlocking the Potential of Biology for Patients; Amgen Astellas Alliance
Amgen: g Unlocking g the Potential of Biology gy for Patients • Pioneering research • Innovative medicines • World‐class manufacturing Amgen g Astellas Alliance • Patient‐focused • Complementary capabilities • Medicines to address unmet medical needs in Japan
Slide 9: Amgen Astellas Alliance - Hyperlipidemia
Amgen g Astellas Alliance Molecule Lead Indication Mode of Action AMG 145 Hyperlipidemia Anti‐PCSK‐9 mAb Romosozumab* Osteoporosis Anti‐Sclerostin mAb (AMG 785) Rilotumumab Gastric cancer Anti‐HGF mAb (AMG 102) AMG 337 Gastric cancer MET inhibitor Acute lymphoblastic leukemia Blinatumomab (ALL) and
Slide 10: Osteoporosis and Gastric Cancer
Osteoporosis p Romosozumab (AMG 785) • Human monoclonal antibody • Anti-Sclerostin mAb Small Molecule Antibody Oncolytic Vaccine Protein/Peptibody Gastric Cancer Rilotumumab (AMG 102) Gastric Cancer: Both Sexes, All Ages • Human monoclonal antibody China 464,439 • Anti-HGF mAb Japan 102,040 Russia 4
Slide 11: Acute Lymphoblastic Leukemia / Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia/ Non-Hodgkin’s g Lymphoma y p Blinatumomab (AMG 103) • Bispecific antibody • Anti-CD19 BiTE® Small Molecule Antibody Oncolytic Vaccine Protein/Peptibody Deliveringg important p medicines to patients in J Japan fighti g serious fighting i illnesses